Thomas Weisel Partners
Thomas Weisel Partners called Thermo Fisher's planned $260 million acquisition of Fermentas a "synergistic tuck-in deal" that "bolsters Thermo's capabilities in the high-growth PCR market."
Cepheid Shares Downgraded by Bank
An investment analyst downgraded the shares to "market perform," citing the current hospital spending environment.
Bank Ups 2010 Revenue, EPS Estimates for Waters
The investment bank upped its estimates for the firm, citing a recent meeting with executives who said that they continue to see a stabilization in end markets.
Helicos Cuts Q3 Net Loss by Almost 40 Percent; Rules out Potential Sale of Company
Helicos said that based on its "improving standalone prospects and current market valuation" that it has disengaged from discussions involving a potential sale of the company.
A Thomas Weisel Partners report found that some researchers do not plan to use the stimulus cash to buy equipment, such as mass specs. Rather, a majority said they would use the cash to hire additional personnel.
Apr 8, 2009